TLR4 Asp299Gly (rs4986790) polymorphism and coronary artery disease: a meta-analysis
Authors:
Open Access
Abstract
Background.Previous studies have shown conflicting results on the association between toll-like receptor 4 (TLR4) Asp299Gly (rs4986790) polymorphism and coronary artery disease (CAD). The aim of this study was to evaluate the influence of TLR4 Asp299Gly polymorphism on CAD risk, CRP level and the number of stenotic coronary arteries, as well as to investigate whether G allele carriers would benefit more from statin treatment.Methods.PubMed, EMBASE, and CNKI databases were searched until May 2015. All the statistical tests were performed using R version 3.1.2. Odds ratio (OR) and 95% confidence interval (CI) were used to assess the association between TLR4 Asp299Gly polymorphism and CAD risk, the number of stenotic vessels, and the incidence of cardiovascular events according to statin-treated patients. Weighted mean difference (WMD) was calculated for the association between Asp299Gly and CRP level.Results.Overall, 12 case-control studies with 10,258 cases and 5,891 controls were included, and no association of TLR4Asp299Gly polymorphism with CAD was found (G allele vs. A allele: OR = 0.97, 95% CI [0.81–1.17],P= 0.75; AA vs. GG + AG: OR = 0.97, 95% CI [0.80–1.18],P= 0.76; GG vs. AG + AA: OR = 1.08, 95% CI [0.57–2.02],P= 0.82; AG vs. AA + GG: OR = 1.03, 95% CI [0.85–1.25],P= 0.74). Also, no association was noted between Asp299Gly and CRP level (WMD = −0.10, 95% CI [−0.62, 0.41],P= 0.69). Furthermore, no synergistic effect of statin and 299Gly was reported (Statin_AA vs. Statin_AG/GG: OR = 1.12, 95% CI [0.41–3.09],P= 0.82).Discussion.This meta-analysis suggests no association of TLR4 Asp299Gly polymorphism with CAD and CRP level. It is further indicated that the G allele carriers may not benefit more from statin treatment. Further studies should include large sample size and high-quality literature to understand this issue in depth.Keywords
Funding Information
- National Natural Science Foundation of China (81173399)
This publication has 55 references indexed in Scilit:
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionNew England Journal of Medicine, 2012
- Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary interventionPharmacogenetics and Genomics, 2010
- The Additive Contribution from Inflammatory Genetic Markers on the Severity of Cardiovascular DiseaseScandinavian Journal of Immunology, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Cholesterol Ester Transfer Protein, Interleukin-8, Peroxisome Proliferator Activator Receptor Alpha, and Toll-Like Receptor 4 Genetic Variations and Risk of Incident Nonfatal Myocardial Infarction and Ischemic StrokeThe American Journal of Cardiology, 2008
- Rarity of TLR4 Asp299Gly and Thr399Ile Polymorphisms in the Korean PopulationYonsei Medical Journal, 2008
- TLR4polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humansProceedings of the National Academy of Sciences, 2007
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986